

Maddalena Barba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1940577/publications.pdf>

Version: 2024-02-01

124
papers

3,120
citations

172207

29
h-index

243296

44
g-index

124
all docs

124
docs citations

124
times ranked

4705
citing authors

#	ARTICLE	IF	CITATIONS
1	Parenteral anticoagulation in ambulatory patients with cancer. The Cochrane Library, 2023, 2023, CD006652.	1.5	42
2	Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2023, 2023, CD006650.	1.5	65
3	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. Critical Reviews in Oncology/Hematology, 2021, 157, 103176.	2.0	11
4	MicroRNA-based signatures impacting clinical course and biology of ovarian cancer: a miRNomics study. Biomarker Research, 2021, 9, 57.	2.8	10
5	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. The Cochrane Library, 2021, 2021, CD006466.	1.5	2
6	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	1.4	6
7	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2021, 2021, CD006649.	1.5	4
8	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. International Journal of Cancer, 2020, 146, 1917-1929.	2.3	4
9	Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane. Medicine (United States), 2020, 99, e21211.	0.4	1
10	Cancer patients and coronavirus disease 2019: evidence in context. Journal of Translational Medicine, 2020, 18, 315.	1.8	6
11	Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Journal of Experimental and Clinical Cancer Research, 2020, 39, 279.	3.5	32
12	Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives. International Journal of Molecular Sciences, 2020, 21, 3528.	1.8	30
13	Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors. Immunotherapy, 2020, 12, 675-679.	1.0	3
14	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. Journal of Cellular Physiology, 2020, 235, 7900-7910.	2.0	19
15	Observational Multicenter Study on the Prognostic Relevance of Coagulation Activation in Risk Assessment and Stratification in Locally Advanced Breast Cancer. Outline of the ARIAS Trial. Cancers, 2020, 12, 849.	1.7	2
16	Anticoagulation for the initial treatment of venous thromboembolism in people with cancer. The Cochrane Library, 2019, 2019, CD006649.	1.5	26
17	Anticoagulation for people with cancer and central venous catheters. The Cochrane Library, 2019, 2019, CD006468.	1.5	28
18	Anticoagulation for perioperative thromboprophylaxis in people with cancer. The Cochrane Library, 2019, 2019, CD009447.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 111.	6.9	93
20	Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1924-1934.	0.5	60
21	Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985319.	1.4	2
22	Long-Term Safety and Real-World Effectiveness of Trastuzumab in Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 254.	1.0	27
23	Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios. <i>Journal of Cancer</i> , 2019, 10, 5903-5914.	1.2	16
24	Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor- α positive, advanced breast cancer: A real-world experience. <i>Journal of Cellular Physiology</i> , 2019, 234, 7708-7717.	2.0	21
25	The clinical significance of PD-L1 in advanced gastric cancer is dependent on <i>ARID1A</i> mutations and ATM expression. <i>Oncolmmunology</i> , 2018, 7, e1457602.	2.1	11
26	Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab. <i>Cancer Biology and Therapy</i> , 2018, 19, 328-334.	1.5	12
27	GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 1396-1401.	2.0	17
28	Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting. <i>Journal of Cellular Physiology</i> , 2018, 233, 2313-2323.	2.0	33
29	Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. <i>Journal of Cellular Physiology</i> , 2018, 233, 2572-2580.	2.0	11
30	Coexisting YAP expression and TP53 missense mutations delineates a molecular scenario unexpectedly associated with better survival outcomes in advanced gastric cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 247.	1.8	6
31	Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting. <i>Journal of Translational Medicine</i> , 2018, 16, 129.	1.8	16
32	Indirect Basal Metabolism Estimation in Tailoring Recombinant Human TSH Administration in Patients Affected by Differentiated Thyroid Cancer: A Hypothesis-Generating Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 37.	1.5	4
33	Deep sequencing and pathway-focused analysis revealed multigene oncogene signatures predicting survival outcomes in advanced colorectal cancer. <i>Oncogenesis</i> , 2018, 7, 55.	2.1	12
34	Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 22.	1.8	13
35	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. <i>International Journal of Cancer</i> , 2017, 140, 2587-2595.	2.3	30
36	Body mass index modifies the relationship between γ -H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer. <i>BMC Cancer</i> , 2017, 17, 101.	1.1	12

#	ARTICLE	IF	CITATIONS
37	ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study. <i>Future Oncology</i> , 2017, 13, 1517-1525.	1.1	4
38	Expression of phosphorylated Hippo pathway kinases (MST1/2 and LATS1/2) in HER2-positive and triple-negative breast cancer patients treated with neoadjuvant therapy. <i>Cancer Biology and Therapy</i> , 2017, 18, 339-346.	1.5	22
39	Association between AXL, Hippo Transducers, and Survival Outcomes in Male Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 2246-2252.	2.0	9
40	Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study. <i>Scientific Reports</i> , 2017, 7, 10597.	1.6	16
41	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. <i>Scientific Reports</i> , 2017, 7, 8078.	1.6	14
42	A Real-World Multicentre Retrospective Study of Paclitaxel+Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer. <i>Journal of Cellular Physiology</i> , 2017, 232, 1571-1578.	2.0	16
43	Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation. <i>The Cochrane Library</i> , 2017, 12, CD006466.	1.5	17
44	Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. <i>Oncotarget</i> , 2017, 8, 54528-54536.	0.8	10
45	A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. <i>Oncotarget</i> , 2017, 8, 56921-56931.	0.8	53
46	Is there a role for adjuvant pertuzumab in HER2-positive breast cancer?. <i>Translational Cancer Research</i> , 2017, 6, S1281-S1284.	0.4	0
47	Metabolic Determinants and Anthropometric Indicators Impact Clinical-pathological Features in Epithelial Ovarian Cancer Patients. <i>Journal of Cancer</i> , 2016, 7, 516-522.	1.2	4
48	Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment. <i>Oncolmmunology</i> , 2016, 5, e1160187.	2.1	30
49	Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. <i>Expert Review of Vaccines</i> , 2016, 15, 1327-1336.	2.0	79
50	Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial. <i>Journal of Cellular Physiology</i> , 2016, 231, 2541-2547.	2.0	12
51	Presurgical window of opportunity trial design as a platform for testing anticancer drugs: Pros, cons and a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 132-142.	2.0	9
52	HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes. <i>Scientific Reports</i> , 2016, 6, 35121.	1.6	6
53	Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin. <i>Journal of Cellular Physiology</i> , 2016, 231, 986-991.	2.0	12
54	Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 62.	3.5	24

#	ARTICLE	IF	CITATIONS
55	Body mass index and treatment outcomes following neoadjuvant therapy in women aged 45Åy or younger: Evidence from a historic cohort. <i>Cancer Biology and Therapy</i> , 2016, 17, 470-476.	1.5	6
56	DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis. <i>PLoS ONE</i> , 2016, 11, e0149872.	1.1	11
57	â€œTriple positiveâ€-early breast cancer: an observational multicenter retrospective analysis of outcome. <i>Oncotarget</i> , 2016, 7, 17932-17944.	0.8	33
58	The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer. <i>Oncotarget</i> , 2016, 7, 43188-43198.	0.8	35
59	The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. <i>Expert Reviews in Molecular Medicine</i> , 2015, 17, e14.	1.6	75
60	Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. <i>Journal of Hematology and Oncology</i> , 2015, 8, 53.	6.9	32
61	Triple positive breast cancer: A distinct subtype?. <i>Cancer Treatment Reviews</i> , 2015, 41, 69-76.	3.4	83
62	Anthropometric, Metabolic and Molecular Determinants of Human Epidermal Growth Factor Receptor 2 Expression in Luminal B Breast Cancer. <i>Journal of Cellular Physiology</i> , 2015, 230, 1708-1712.	2.0	5
63	Efficacy of chemotherapy in metastatic male breast cancer patients: a retrospective study. <i>Journal of Experimental and Clinical Cancer Research</i> , 2015, 34, 26.	3.5	15
64	Metformin and breast cancer: Basic knowledge in clinical context. <i>Cancer Treatment Reviews</i> , 2015, 41, 441-447.	3.4	13
65	Androgen receptor and antiandrogen therapy in male breast cancer. <i>Cancer Letters</i> , 2015, 368, 20-25.	3.2	17
66	Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis. <i>Oncotarget</i> , 2015, 6, 42773-42780.	0.8	14
67	Emerging Biological Treatments for Uterine Cervical Carcinoma. <i>Journal of Cancer</i> , 2014, 5, 86-97.	1.2	51
68	Cancer stem cells: are they responsible for treatment failure?. <i>Future Oncology</i> , 2014, 10, 2033-2044.	1.1	13
69	Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 599-607.	1.1	39
70	Parenteral anticoagulation in ambulatory patients with cancer. , 2014, , CD006652.		56
71	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. <i>The Cochrane Library</i> , 2014, , CD006649.	1.5	52
72	Hot flushes in women with breast cancer: state of the art and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 185-198.	1.1	4

#	ARTICLE	IF	CITATIONS
73	Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer. <i>Gastric Cancer</i> , 2014, 17, 718-724.	2.7	20
74	Antiandrogen therapy in metastatic male breast cancer: results from an updated analysis in an expanded case series. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 73-80.	1.1	24
75	Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. <i>The Cochrane Library</i> , 2014, , CD006650.	1.5	152
76	Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. <i>Breast Cancer Research and Treatment</i> , 2014, 147, 227-235.	1.1	19
77	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2014, , CD006466.		9
78	Mortality trend for liver cancer in a hyperendemic area of hepatitis C virus infection in southern Italy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 245-246.	0.8	2
79	Anticoagulation for people with cancer and central venous catheters. <i>The Cochrane Library</i> , 2014, , CD006468.	1.5	41
80	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2014, , CD006466.		13
81	Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. <i>The Cochrane Library</i> , 2014, , CD009447.	1.5	32
82	p53 status as effect modifier of the association between pre-treatment fasting glucose and breast cancer outcomes in non diabetic, HER2 positive patients treated with trastuzumab. <i>Oncotarget</i> , 2014, 5, 10382-10392.	0.8	11
83	The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy. <i>Oncotarget</i> , 2014, 5, 9619-9625.	0.8	35
84	Molecular profiles of screen detected vs. symptomatic breast cancer and their impact on survival: results from a clinical series. <i>BMC Cancer</i> , 2013, 13, 15.	1.1	44
85	FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 67.	3.5	22
86	Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 49.	3.5	15
87	Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 119-123.	1.1	32
88	Cancer mortality trends between 1988 and 2009 in the metropolitan area of Naples and Caserta, Southern Italy. <i>Cancer Biology and Therapy</i> , 2013, 14, 1113-1122.	1.5	13
89	Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. <i>PLoS ONE</i> , 2013, 8, e69269.	1.1	45
90	Estrogen Metabolism and Mammographic Density in Postmenopausal Women: A Cross-Sectional Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1582-1591.	1.1	19

#	ARTICLE	IF	CITATIONS
91	The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge records. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 96.	3.5	12
92	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006466.		13
93	Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006652.		52
94	Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. , 2011, , CD006650.		30
95	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		16
96	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		8
97	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2011, , CD006649.		21
98	Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2011, , CD006652.		10
99	Reducing the risk of overdiagnosis in lung cancer: A support from molecular biology. <i>Journal of Cellular Physiology</i> , 2011, 226, 2213-2214.	2.0	9
100	Wasting lives: The effects of toxic waste exposure on health. The case of Campania, Southern Italy. <i>Cancer Biology and Therapy</i> , 2011, 12, 106-111.	1.5	33
101	Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. , 2010, , CD006466.		9
102	An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation. <i>Health and Quality of Life Outcomes</i> , 2010, 8, 26.	1.0	28
103	Metformin, diet and breast cancer: An avenue for chemoprevention. <i>Cell Cycle</i> , 2009, 8, 2661-2661.	1.3	33
104	Is it Time to Test Metformin in Breast Cancer Prevention Trials? a Reply to the Authors. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2565-2565.	1.1	3
105	Association between mode of breast cancer detection and diagnosis delay. <i>Breast</i> , 2009, 18, 382-386.	0.9	11
106	The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. <i>Clinical Endocrinology</i> , 2009, 70, 661-670.	1.2	30
107	Urinary estrogen metabolites and prostate cancer: a case-control study and meta-analysis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2009, 28, 135.	3.5	16
108	Thromboprophylaxis for patients with cancer and central venous catheters. <i>Cancer</i> , 2008, 112, 2483-2492.	2.0	81

#	ARTICLE	IF	CITATIONS
109	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. <i>Cancer</i> , 2008, 113, 1685-1694.	2.0	33
110	Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 21.	3.5	51
111	Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. <i>Journal of Experimental and Clinical Cancer Research</i> , 2008, 27, 4.	3.5	37
112	Indicators of Sexual and Somatic Development and Adolescent Body Size in Relation to Prostate Cancer Risk: Results From a Case-Control Study. <i>Urology</i> , 2008, 72, 183-187.	0.5	15
113	Low-Molecular-Weight Heparin vs Unfractionated Heparin for Perioperative Thromboprophylaxis in Patients With Cancer<subtitle>A Systematic Review and Meta-analysis</subtitle>. <i>Archives of Internal Medicine</i> , 2008, 168, 1261.	4.3	75
114	Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. , 2008, , CD006650.		21
115	Equol Status Modifies the Association of Soy Intake and Mammographic Density in a Sample of Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 33-42.	1.1	29
116	Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. , 2008, , CD006649.		9
117	Extended perioperative thromboprophylaxis in patients with cancer. <i>Thrombosis and Haemostasis</i> , 2008, 100, 1176-1180.	1.8	63
118	Oral anticoagulation for prolonging survival in patients with cancer. , 2007, , CD006466.		25
119	Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters. , 2007, , CD006468.		28
120	Parenteral anticoagulation for prolonging survival in patients with cancer who have no other indication for anticoagulation. , 2007, , CD006652.		55
121	Perinatal Exposures and Breast Cancer Risk in the Western New York Exposures and Breast Cancer (WEB) Study. <i>Cancer Causes and Control</i> , 2006, 17, 395-401.	0.8	34
122	Erythrocyte Membrane Phospholipid Composition as a Biomarker of Dietary Fat. <i>Annals of Nutrition and Metabolism</i> , 2006, 50, 95-102.	1.0	63
123	Basal growth hormone concentrations in blood and the risk for prostate cancer: A case-control study. <i>Prostate</i> , 2005, 64, 109-115.	1.2	12
124	Lifetime total and beverage specific - alcohol intake and prostate cancer risk: a case-control study. <i>Nutrition Journal</i> , 2004, 3, 23.	1.5	14